Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes

Jinhua Dong,Yingying Zhang,Jingsheng Zhou,Shuhui Mao,Jianfen Tang,Suping Li,Qiang Ma,Ling Ai,Wei Wang,Guanghao Zhu,Huijing Shao,Yingdi Meng,Huaiwen Chen,Danqing Chen
DOI: https://doi.org/10.1080/17435889.2024.2368449
Abstract:Aim: To evaluate a liposome complex conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for the treatment of pre-eclampsia (PE).Methods: In in vitro experiments, the transfection rate, silencing effect and cytotoxicity were determined. In the in vivo PE model, the siRNA distribution, mean arterial pressure, 24-h urine protein concentration, serum sFlt1 concentration, number of viable fetuses and placental weight were measured.Results: The nanomedicine effectively reduced the expression of sFIt1 and had a strong ability to target placental tissues. It could significantly reduce the symptoms of pre-eclampsia and improve pregnancy outcomes in PE model rats.Conclusion: The constructed nanomedicine can improve pregnancy outcomes in a rat model of pre-eclampsia and provides a new strategy for the treatment of pre-eclampsia.
What problem does this paper attempt to address?